The company's economic evidence was limited to people with genotypes 1–6 who have had direct-acting antiviral (DAA) and those who had not had a DAA before in people with genotype 3 hepatitis C. Therefore sofosbuvir–velpatasvir–voxilaprevir is recommended for these groups for treating chronic hepatitis C (further details provided in the full text of the guidance).